Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Shares Outstanding (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Shares Outstanding for 7 consecutive years, with $194.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.49% to $194.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $194.8 million through Dec 2025, up 2.49% year-over-year, with the annual reading at $194.8 million for FY2025, 2.49% up from the prior year.
  • Shares Outstanding hit $202.4 million in Q4 2025 for BridgeBio Pharma, up from $200.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $202.4 million in Q4 2025 to a low of $3.2 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $141.4 million across 5 years, with a median of $167.8 million in 2023.
  • Biggest YoY gain for Shares Outstanding was 6001.98% in 2021; the steepest drop was 97.38% in 2021.
  • Year by year, Shares Outstanding stood at $147.3 million in 2021, then grew by 2.23% to $150.6 million in 2022, then increased by 16.24% to $175.1 million in 2023, then increased by 8.55% to $190.0 million in 2024, then grew by 2.49% to $194.8 million in 2025.
  • Business Quant data shows Shares Outstanding for BBIO at $194.8 million in Q4 2025, $200.2 million in Q3 2025, and $191.2 million in Q2 2025.